The expansion of Stouffville plant and equipment deployment will allow Teva Canada to produce one billion more tablets of prescription based generic medicines per year.
Further, the expansion not only increases the supply of generic prescription drugs for Ontarians but also enables the pharma company to compete globally with new specialized generic prescription medications.
Teva Canada president and CEO Barry Fishman their expanded plant and new equipment will enable them to increase their capacity to service the needs of patients in Ontario and across Canada.